Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAESTRAL trial of moxifloxacin versus amoxicillin-clavulanic acid for acute exacerbations of chronic bronchitis
NL-OMON32177Phase 4Active, not recruiting
- Sponsor
- Bayer
- Start
- Jan 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) comparing Moxifloxacin with Amoxicillin-clavulanic acid (2 arms). Primary endpoint: Clinical failure rate at 8 weeks post-therapy. Started Jan 2009; status: active, not recruiting.
02
Drugs
moxifloxacinamoxicillin + clavulanate
03
Conditions
chronic bronchitis (CB)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON32177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32177.